-transparent.png){kind=logo}
Three patients with ulcerative colitis in the active stage demonstrated reduced levels of F XIII activity and F XIII subunit A (61 and 80.3%, respectively). Because of the lack of clinical improvement during conservative therapy, the patients were treated additionally with F XIII concentrate (Fibrogammin HS, Behring, FRG) for 10 days. The substitution resulted in an increase in F XIII activity (144.3%) and F XIII subunit A (238%) as well as in a marked improvement in symptoms.
Related Publications
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
February 1995,
Lancet (London, England),
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
February 1989,
Zeitschrift fur Gastroenterologie,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
October 1994,
Medizinische Klinik (Munich, Germany : 1983),
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
February 1987,
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
January 1994,
Digestion,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
August 1989,
Blut,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
June 1991,
The American journal of gastroenterology,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
July 1972,
Harefuah,
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
March 1972,
Deutsche medizinische Wochenschrift (1946),
R Lorenz, and
M Heinmüller, and
M Classen, and
N Tornieporth, and
T Gain
July 2005,
Gut,
